COMPANY PROFILE

Phoenix Molecular Designs

Explore full profile

Biotechnology company designing precise cancer therapeutics by targeting essential kinases

Vancouver, CanadaFounded 2012Biotech & Life Sciences

Valuation $50–100M Last recorded · 2019

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Phoenix Molecular Designs

Phoenix Molecular Designs, based in Vancouver, is a biotechnology company founded by renowned Breast Cancer researcher Dr. Sandra Dunn. The company is dedicated to developing innovative targeted small molecule drugs specifically designed to treat Triple Negative Breast Cancer (TNBC). Phoenix Molecular Designs operates in the precision medicine market, focusing on creating treatments based on the genetic composition of tumors. This approach aims to provide better solutions for cancer treatments and improve the lives of patients. The business model revolves around drug discovery and development, targeting specific cancer types with high unmet medical needs. Revenue is generated through the development and commercialization of these targeted therapies, potentially in collaboration with larger pharmaceutical companies.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2012
Headquarters: Vancouver, Canada
Employees: 11
Open positions: None listed
Dealroom signal: 58.8/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES AEquity / VC	Dec 2020	$4.7M	$19M	Undisclosed	—
SEED✓Equity / VC	Nov 2019	$9.3M	$37M	Pallasite Ventures	—

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Phoenix Molecular Designs website traffic

Latest recorded traffic for Phoenix Molecular Designs is 3.4K monthly website visits, up 54.5% over the last three months. Phoenix Molecular Designs's team declined 21.4% over the past year.

Latest monthly visits3.4K 3-month web change+54.5% 1-year team growth-21.4%

Monthly website visitsJun 2018–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
DPDISCO PharmaceuticalsBiotechnological research as well as the development, production and distribution of biotechnological products and solutions of all kinds	Cologne, Germany	Operational	37	$62M	$158M
RLReverie LabsReverie Labs (YC W18) optimizes potential medicines using machine learning	Cambridge, United States	Acquired
HEHelixNanoUses artificial intelligence to help cure genetic diseases	Cambridge, United States	Operational
CSCarevive SystemsProviding personalized and dynamic cancer care plans for patients	North Miami Beach, United States	Acquired
ANAnnoroadA leading developer and marketer on genomic innovation technologies for research and clinical market	Dongcheng District, China	Operational
BIBioNTechDevelops personalized immunotherapies with a focus on cancer medicine	Mainz, Germany	Operational
ARargenxPlatform for antibody lead choice that supports the discovery of human antibody therapeutics	Ghent, Belgium	Operational
ONOncoImmunityDeveloping bioinformatics software that has the ability to empower precision cancer immunotherapy	Oslo, Norway	Acquired

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

0 profiles shownExplore the complete relationship graph →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

PVPallasite Ventures

Other known investors4 additional known investors

AVAventrock Ventures
AVAventrock Ventures
EVEshelman Ventures
FVFlucas Ventures

Talent

Book a demo to see the people

Team profiled 7 named & role-tagged

Founders /100 quality score

Key operators 2 quality /100

Potential founders likely future founders

Startup mafia alumni-founded startups

Talent movements in · out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country

Workforce by country

2 countries with
team presence

🇺🇸 United States50%

🇨🇦 Canada50%

2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Phoenix Molecular Designs on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Phoenix Molecular Designs’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Request a free trial

Takes under a minute. Already use Dealroom? Log in.